

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2021/099783 A1**

(43) International Publication Date  
27 May 2021 (27.05.2021)

(51) International Patent Classification:

A61K 31/05 (2006.01) A61P 25/08 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2020/052944

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

18 November 2020 (18.11.2020)

**Published:**

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1916977.0 21 November 2019 (21.11.2019) GB

(71) Applicant: **GW RESEARCH LIMITED** [GB/GB]; Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB).

(72) Inventors: **GUY, Geoffrey**; GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **KNAPPERTZ, Volker**; GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **WHALLEY, Benjamin**; GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **WOOLLEY-ROBERTS, Marie**; GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB).

(74) Agent: **HGF LIMITED**; Document Handling - HGF (Manchester), 1 City Walk, Leeds Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CANNABIDIOL-TYPE CANNABINOID COMPOUND

(57) Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.

WO 2021/099783 A1

## CANNABIDIOL-TYPE CANNABINOID COMPOUND

### FIELD OF THE INVENTION

5 [0001] The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament.

[0002] The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV).

[0003] The cannabinoid can be produced by synthetic means.

10 [0004] Disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease. In addition, a method for the production of 6-OH CBDV is described.

### BACKGROUND TO THE INVENTION

[0005] Cannabinoids are natural and synthetic compounds structurally or pharmacologically  
15 related to the constituents of the cannabis plant or to the endogenous agonists (endocannabinoids) of the cannabinoid receptors CB1 or CB2. The only way in nature in which these compounds are produced is by the cannabis plant. Cannabis is a genus of flowering plants in the family *Cannabaceae*, comprising the species *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis* (sometimes considered as part of *Cannabis sativa*).

20 [0006] Cannabis plants comprise a highly complex mixture of compounds. At least 568 unique molecules have been identified. Among these compounds are cannabinoids, terpenoids, sugars, fatty acids, flavonoids, other hydrocarbons, nitrogenous compounds, and amino acids.

[0007] Cannabinoids exert their physiological effects through a variety of receptors  
25 including, but not limited to, adrenergic receptors, cannabinoid receptors (CB1 and CB2), GPR55, GPR3, or GPR5. The principle cannabinoids present in cannabis plants are cannabinoid acids  $\Delta$ 9-tetrahydrocannabinolic acid ( $\Delta$ 9-THCA) and cannabidiolic acid (CBDA) with small amounts of their respective neutral (decarboxylated) cannabinoids. In addition, cannabis may contain lower levels of other minor cannabinoids. "Chemical composition,  
30 pharmacological profiling, and complete physiological effects of these medicinal plants, and more importantly the extracts from cannabis, remain to be fully understood." Lewis, M. M. et al., ACS Omega, 2, 6091–6103 (2017).

[0008] Crude extracts from cannabis plants containing CBD have been used by patients  
35 suffering from diseases and disorders. However, such crude products are unsuitable for use in pharmaceutical formulations. Those seeking to prepare more consistent CBD preparations for use in treating diseases or disorders have made a concerted effort to either prepare CBD

synthetically or attempt to remove all compounds other than CBD, particularly psychoactive compounds such as THC, from plant derived cannabinoids. See for example US 2014/0298511.

5 **[0009]** The present invention encompasses the surprising discovery that a metabolite of CBDV has therapeutic efficacy. This compound, 6-hydroxy cannabidivarin (6-OH CBDV) can be produced synthetically and may be used in a purified form.

**[0010]** Cannabinoids are a class of compounds which many of which can be derived naturally from the cannabis plant or produced synthetically via chemical synthesis.

10 **[0011]** More than 100 different cannabinoids produced by cannabis have been identified. These cannabinoids can be split into different groups as follows: phytocannabinoids; endocannabinoids and synthetic cannabinoids (which may be novel cannabinoids or synthetically produced versions of phytocannabinoids or endocannabinoids).

15 **[0012]** Phytocannabinoids are cannabinoids that originate from nature and can be found in the cannabis plant. Phytocannabinoids can be isolated from plants to produce a highly purified extract. Phytocannabinoids may be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids from plant material. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form. Phytocannabinoids can only be produced from plants, however versions of phytocannabinoids may be produced synthetically  
20 via chemical synthesis.

**[0013]** Endocannabinoids are endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the mammalian central nervous system (including the brain) and peripheral nervous system. The endocannabinoid system is involved in regulating a variety of physiological and cognitive  
25 processes including fertility, pregnancy, during pre- and postnatal development, appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of cannabis.

**[0014]** Synthetic cannabinoids are compounds that have a cannabinoid-like structure and are manufactured using chemical means rather than by the plant.

**[0015]** Certain cannabinoids are described in more detail below.

30 **[0016]** Cannabidiol (CBD) is a major cannabinoid constituent of Cannabis species, such as the hemp plant (*Cannabis sativa*). Unlike other cannabinoids, such as THC, cannabidiol does not bind CB1 or CB2, or its binding to the receptors is negligible in terms of inducing a pharmacological effect. Thus, cannabidiol does not cause the central or peripheral nervous system effects mediated by the CB1 or CB2 receptors. CBD has little or no psychotropic

(cannabimimetic) activity and its molecular structure and properties are substantially different from those of other cannabinoids.

**[0017]** CBD and CBDV administration have been the subject of research in an attempt to provide an alternative treatment for various diseases and disorders which may respond to such treatment.

**[0018]** There have been many studies done in animals to determine the metabolism of CBD and CBDV. The pharmacokinetics of CBD and CBDV are complex, mainly due to a substantial first pass effect. This in turn causes the bioavailability of oral CBD to be poor in humans and other species.

**[0019]** The most abundant metabolites of CBD are hydroxylated 7-carboxy derivatives of CBD which include: 2"-OH-7-COOH,3",4",5"-trior CBD; CBD-glucuronide; 4"-OH-7-COOH CBD; 2"-OH-7-COOH CBD; 10-OH-7-COOH CBD; 3"-OH-7-COOH CBD; 7-OH-3"-COOH,4",5"-dior CBD; 7-COOH-8,9-dihydro-8,9-diOH CBD; 1"-OH-7-COOH CBD; 6-OH-42-COOH,5"-nor CBD; 6-OH-3"-COOH,4",5"-dior CBD; 7-COOH CBD; 7-OH-4"-COOH,5"-nor CBD; 4"-COOH,5"-nor CBD; 7-OH CBD; 8,9-dihydro-7,8,9-triOH CBD; cannabiol; 3"-COOH,4",5"-dior CBD; 2"-COOH,3",4",5"-trior CBD; 2",6-diOH,3",4",5"-trior CBD,6,7-diOH CBD; 7-OH-1"-COOH,2",3",4",5"-tetranor CBD; 6-OH CBD; 7-OH-5"-COOH CBD; 1"-COOH,2",3",4",5"-tetranor CBD; 6-OH-1"-COOH,2",3",4",5"-tetranor CBD and 6-OH-5"-COOH CBD (Ujvary and Hanus, 2016).

**[0020]** Although it is currently unknown which metabolites occur for the CBDV molecule, it is likely that similar metabolites exist for CBDV as for CBD, however the metabolites will have a propyl sidechain rather the pentyl sidechain which exists on the CBD molecule.

**[0021]** The patent US 6,630,507 describes numerous analogues of cannabidiol. The compound 6-OH CBD is detailed in the document however there are no data presented to provide evidence that this compound may have any efficacy as a therapeutic agent.

**[0022]** Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis. THC is a partial agonist at the CB1 and CB2 receptors. Synthetic THC or dronabinol is approved for the treatment of loss of appetite in AIDS patients and nausea and vomiting caused by cancer chemotherapy.

**[0023]** Of the over 100 natural cannabinoids identified in *Cannabis sativa*, seven have been classified as CBD-type compounds, these cannabinoids have the same absolute configuration as CBD. These are: CBD, Cannabidiolic acid (CBDA), Cannabidivarin (CBDV), Cannabidivarin acid (CBDVA), Cannabidiol-C1 (CBD-C1), Cannabidiol-C4 (CBD-C4), Cannabidiol-C6 (CBD-C6) and Cannabidiol monomethyl ether (CBDM).

[0024] Cannabidiolic acid (CBDA) is the main form in which CBD exists in the cannabis plant. It is converted into CBD after decarboxylation.

[0025] Cannabidivarin (CBDV) is a homolog of CBD, with the sidechain shortened by two methylene bridges. CBDV is a non-psychoactive cannabinoid and has been shown to have anti-convulsant activity in a mouse model of epilepsy.

[0026] Cannabidiol-C1 (CBD-C1) also known as cannabidiolcol is a homolog of CBD, with the sidechain shortened by four methylene bridges. CBD-C1 occurs naturally in plants producing CBD but has not been shown to have any therapeutic effects.

[0027] Cannabidiol-C4 (CBD-C4) also known as nor-cannabidiol is a homolog of CBD, with the sidechain shortened by one methylene bridge. CBD-C4 occurs naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

[0028] Cannabidiol-C6 (CBD-C6) is a homolog of CBD, with the sidechain increased by one methylene bridge. CBD-C6 may occur naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

[0029] The present invention demonstrates data for the first time to indicate that the compound 6-hydroxy cannabidivarin may have therapeutic benefit.

#### BRIEF SUMMARY OF THE DISCLOSURE

[0030] In accordance with a first aspect of the present invention there is provided 6-hydroxy cannabidivarin (6-OH CBDV) for use as a medicament.

[0031] Preferably the 6-OH CBDV is present as a synthetic compound. Alternatively, the 6-OH CBDV is present as a pure and isolated compound.

[0032] Preferably the dose of 6-OH CBDV is greater than 100 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 250 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 500 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 750 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 1000 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 1500 mg/kg/day.

[0033] Alternatively, the dose of 6-OH CBDV is less than 100 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 50 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 20 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 10 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 5 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 1mg/kg/day. More preferably the dose of 6-OH CBDV is less than 0.5 mg/kg/day.

[0034] In accordance with a second aspect of the present invention there is provided a composition for use as a medicament comprising 6-hydroxy cannabidivarin (6-OH CBDV), and one or more pharmaceutically acceptable excipients.

[0035] In accordance with a third aspect of the present invention there is provided a 6-hydroxy cannabidivarin (6-OH CBDV) for use in the treatment of epilepsy. Preferably the epilepsy is treated in a mammal. More preferably the mammal is a human. Alternatively, the mammal is a dog.

[0036] In accordance with a fourth aspect of the present invention there is provided a method for the production of 6-hydroxy cannabidivarin (6-OH CBDV).

10

**BRIEF DESCRIPTION OF THE DRAWINGS**



[0037] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:

[0038] Figure 1 shows the effect of 6-OH CBDV in the MEST test in mouse.

15

**CANNABINOIDS AND THEIR ABBREVIATIONS**

[0039] The cannabinoids described in the present application are listed below along with their standard abbreviations.

|                      |                                       |   |
|----------------------|---------------------------------------|---|
| <p>CBD</p>           | <p>Cannabidiol</p>                    |  |
| <p>6-OH<br/>CBDV</p> | <p>Alpha 6-hydroxy cannabidivarin</p> |  |

20

## DETAILED DESCRIPTION

## EXAMPLE 1: SYNTHETIC PRODUCTION METHOD FOR ALPHA 6-HYDROXY CANNABIDIVARIN (6-OH CBDV)

[0040] As previously described the compound 6-OH CBDV is a metabolite of cannabidiol.

5 [0041] The synthetic pathway described below details a methodology that can be used in order to produce the cannabinoid alpha 6-OH CBDV.

[0042] On the scheme  $R=C_3H_7$


10 [0043] To CBDV (5.00 g, 17.5 mmol) in anhydrous pyridine (20 mL) was added acetic anhydride (5.63 g, 5.20 mL, 55.2 mmol) and the solution was stirred for 4 h. Dichloromethane (300 mL) was added and the solution was washed with water (200 mL), 1M hydrochloric acid (200 mL), saturated aqueous sodium bicarbonate (200 mL), dried ( $MgSO_4$ ) and concentrated to give CBDV diacetate (6.84 g, quantitative), as a yellow oil which was used without further purification.

15 [0044] To CBDV diacetate (4.00 g, 10.8 mmol) in glacial acetic acid (9 mL) and acetic anhydride (4.96 g, 4.59 mL, 48.6 mmol) was added sodium dichromate (3.86 g, 13.0 mmol) and the mixture was stirred at room temperature for 4 days. The resulting solution was diluted with water (150 mL) and extracted with diethyl ether ( $2 \times 150$  mL). The combined organic extracts were washed with saturated aqueous sodium bicarbonate (150 mL), dried ( $MgSO_4$ ) and concentrated to give a yellow oil that was purified using a Biotage Isolera automated  
20 chromatography system under normal phase conditions (silica column, gradient of 5  $\rightarrow$  33 % ethyl acetate in petrol) with detection at 254 nm to give 6-oxo-CBDV diacetate (1.40 g 33 %), as a colourless oil.

[0045]  $R_f = 0.36$  (ethyl acetate - petrol, 1 : 4 v/v)

25 [0046] To lithium aluminium hydride (0.58 g, 15.3 mmol) in diethyl ether (50 mL) at 0 °C was added 6-oxo-CBDV diacetate (1.40 g, 3.64 mmol) in diethyl ether (23 mL) and the mixture was stirred at room temperature for 4 h. The resulting mixture was cooled in an ice bath and cautiously quenched with iced water (100 mL). 1 M Hydrochloric acid (60 mL) was added and the mixture was extracted with diethyl ether (100 mL + 50 mL). The combined organic layers were washed with saturated brine (100 mL), dried ( $MgSO_4$ ) and concentrated to give a pale  
30 yellow oil that was purified using a Biotage Isolera automated chromatography system under normal phase conditions (silica column, gradient of 7  $\rightarrow$  53 % ethyl acetate in petrol) with detection at 254 nm to give 6-oxo-CBDV (0.70 g, 64 %), as a white glassy solid.

[0047]  $R_f = 0.29$  (ethyl acetate - petrol, 3 : 7 v/v)



**[0048]** The resultant material was confirmed to be alpha 6-hydroxy-cannabidivarin (6-OH CBDV). The compound is a yellow glassy semi-solid material with the chemical formula C<sub>19</sub>H<sub>26</sub>O<sub>3</sub> and a molecular weight of 302.4 g/mol.

**[0049]** Purity of the compound was tested by HPLC which was shown to produce a 96.7% pure material.

**[0050]** 6-OH CBDV was stored at -20°C and protected from light until required for testing.

10

## EXAMPLE 2: EVALUATION OF 6-HYDROXY CANNABIDIVARIN (6-OH CBDV) FOR ANTICONVULSANT ACTIVITY USING THE SUPRAMAXIMAL ELECTROSHOCK SEIZURE (MES) TEST IN THE MOUSE

**[0051]** The efficacy of 6-OH CBDV was tested in a mouse model of seizure, the supramaximal electroshock seizure (MES) test.

**[0052]** The supramaximal electroshock seizure (MES) test is widely utilized preclinically to evaluate anti-convulsant properties of molecules and standard anti-epileptic drugs (Loscher *et al.*, 1991).

**[0053]** The MES test is a very stringent model in which mice receive a predetermined high-level electrical stimulus of sufficient intensity to reliably produce tonic hindlimb extensor seizures in 100% of control animals. As such the MES test is a rigorous evaluation of anticonvulsant activity (Swinyard, 1985).

25 **Methods**

[0054] Naïve mice were acclimatised to the procedure room in their home cages, with food and water available *ad libitum*.

[0055] Animals were dosed i.p. according to treatment group.

[0056] The vehicle (10ml/kg i.p. 60 min pre-treatment time) was 1:1:18 vehicle 5% ethanol, 5% kolliphor EL, 90% saline.

[0057] The test compound, alpha 6-OH CBDV was prepared according to the method described in Example 1.

[0058] The test compound, 6-OH CBDV was administered at doses of 3, 10, 30, and 100 mg/kg given at 10ml/kg i.p. 60min pre-treatment time.

10 [0059] The positive control valproate was used at 250mg/kg (10ml/kg i.p. 30min pre-treatment time).

[0060] Mice were individually assessed for the production of a tonic hind limb extensor seizure following a pre-determined high level (30mA: 50Hz) corneally delivered electroshock (0.2 sec duration) of sufficient intensity to reliably produce tonic hindlimb seizures in 100% of control animals.

[0061] Induction of seizure is measured as an all-or-nothing effect scored as either present (+) or absent (0) for each animal.

[0062] Data was collected by an observer unaware of the treatment for each animal and was expressed as the number of +'s or 0's for each treatment group.

20 [0063] The percentage inhibition of relevant vehicle treated group (the protection relative to vehicle treated controls) was then generated.

[0064] Significant differences between individual treatment groups and vehicle-treated groups were assessed using 2-tailed Fisher's Exact Probability test ( $p < 0.05$  considered significant).

25

## **Results**

[0065] Table 1 below demonstrates the data produced in this experiment.

[0066] In the positive control valproate (250 mg/kg) treated group, administered i.p. 30 minutes before the test, all animals were scored as not having a seizure. This result was statistically significant ( $p < 0.001$ ) compared to the vehicle control.

[0067] In the 6-OH CBDV treatment groups, administered i.p. 60 minutes before the test, the dose of 3 and 10 mg/kg 6-OH CBDV only produced a 20% change in seizures compared to the vehicle control which was non-significant.

[0068] However, the doses of 30 and 100 mg/kg 6-OH CBDV enabled all mice to withstand seizures and produced a statistically significant effect compared to vehicle ( $p < 0.001$ ).

35

### **Table 1: Evaluation of effect of 6-OH CBDV in the MES test**

| Treatment | Dose (mg/kg) | N  | Pre-treatment time (mins) | % change from vehicle | Significance    |
|-----------|--------------|----|---------------------------|-----------------------|-----------------|
| Vehicle   | -            | 10 | 60                        | -                     | -               |
| Valproate | 250          | 10 | 30                        | 100%                  | P<0.001         |
| 6-OH CBDV | 3            | 10 | 60                        | 20%                   | Non-significant |
| 6-OH CBDV | 10           | 10 | 60                        | 20%                   | Non-significant |
| 6-OH CBDV | 30           | 10 | 60                        | 100%                  | P<0.001         |
| 6-OH CBDV | 100          | 10 | 60                        | 100%                  | P<0.001         |

### Conclusions

5 [0069] These data demonstrate for the first time a therapeutic effect for the compound 6-OH CBDV.

[0070] These data are significant as they provide heretofore unknown evidence that this cannabinoid may be of therapeutic value.

### 10 EXAMPLE 3: EVALUATION OF 6-HYDROXY CANNABIDIVARIN (6-OH CBDV) FOR ANTICONVULSANT ACTIVITY USING THE MAXIMAL ELECTROSHOCK SEIZURE THRESHOLD (MEST) TEST IN THE MOUSE

[0071] The efficacy of 6-OH CBDV was tested in a mouse model of generalised seizure,  
15 the maximal electroshock seizure threshold (MEST) test.

[0072] The maximal electroshock seizure threshold (MEST) test is widely utilized preclinically to evaluate pro- or anti-convulsant properties of test compounds (Loscher et al., 1991).

[0073] In the MEST test the ability of a drug to alter the seizure threshold current required  
20 to induce hind limb tonic extensor convulsions is measured according to an "up and down" method of shock titration (Kimball et al., 1957). An increase in seizure threshold is indicative of anti-convulsant effect. Antiepileptic drugs including the sodium channel blockers (e.g. lamotrigine) with clinically proven efficacy against generalised tonic-clonic seizures all exhibit anti-convulsant properties in this test in the mouse.

25 [0074] Conversely, a reduction in seizure threshold is indicative of a pro-convulsant effect as observed with known convulsant agents such as picrotoxin.

**[0075]** The ability of a test compound to alter the stimulus intensity, expressed as current (mA), required to induce the presence of tonic hind limb extensor convulsions, is assessed in the MEST. The outcome of the presence (+) or absence (0) of tonic hind limb extensor convulsions observed from a current to produce tonic hind limb extension in 50% of animals in the treatment group ( $CC_{50}$ ) determines the seizure threshold for the treatment group and the effects were then compared to the  $CC_{50}$  of the vehicle control group.

## **Methods**

### **Study Details:**

10 **[0076]** Naïve mice were acclimatised to the procedure room in their home cages for up to 7 days, with food and water available ad libitum.

**[0077]** All animals were weighed at the beginning of the study and randomly assigned to treatment groups based on a mean distribution of body weight across groups. All animals were dosed at 10 mL/kg via intraperitoneal (i.p) injection, with either vehicle, 6-OH CBDV at 3, 10 or 15 30 mg/kg, diazepam at 2.5 mg/kg or sodium valproate at 250 mg/kg.

**[0078]** Animals were individually assessed for the production of a tonic hind limb extensor convulsion at 15 min post-dose for vehicle, at 15, 15 and 30 min post-dose for 6-OH CBDV at 3, 10 and 30 mg/kg respectively, and 30 min post-dose for diazepam and sodium valproate, from a single electroshock.

20 **[0079]** The first animal within a treatment group was given a shock at the expected or estimated  $CC_{50}$  current. For subsequent animals, the current was lowered or raised depending on the convulsions outcome from the preceding animal.

**[0080]** Data generated from each treatment group were used to calculate the  $CC_{50} \pm SEM$  values for the treatment group.

25

### **Test Compounds:**

**[0081]** Vehicle: (5% ethanol, 5% solutol, 90% Saline) was prepared as follows: 2 mL of ethanol, 2 mL of solutol were warmed to 60°C, in 36 mL of saline (1:1:18).

30 **[0082]** Positive controls: diazepam was used at 2.5mg/kg and sodium valproate at 250 mg/kg.

**[0083]** The test compound, alpha 6-OH CBDV was prepared according to the method described in Example 1. 6-OH CBDV was administered at 3, 10 and 30mg/kg (i.p.) in a 1:1:18 ethanol:solutol:0.9% saline formulation.

35

### **Sample Collection:**

[0084] Each animal was humanely killed immediately after production of a convulsion by destruction of the brain from striking the cranium, followed by the confirmation of permanent cessation of the circulation from decapitation under The Humane Killing of Animals under  
5 Schedule 1 to the Animals (Scientific Procedures) Act 1986. Terminal blood and brain collection were performed following decapitation.

[0085] Blood was collected in Lithium-heparin tubes and centrifuged at 4°C for 10 minutes at 1500 x g. The resulting plasma was removed (>100 µL) and split into 2 aliquots of 0.5 mL Eppendorf tubes containing 100 µL of ascorbic acid (100 mg/mL) for stabilisation. Brains were  
10 removed, washed in saline and halved. Each half was placed into separate 2 mL screw cap cryovials, weighed and frozen on cardice.

#### Statistical analysis

[0086] The data for each treatment group were recorded as the number of +’s and 0’s at  
15 each current level employed and this information is then used to calculate the CC<sub>50</sub> value (current required for 50% of the animals to show seizure behaviour) ± standard error.

[0087] 6-OH CBDV effects were also calculated as percentage change in CC<sub>50</sub> from the vehicle control group.

Significant difference between drug-treated animals and controls were assessed according to  
20 Litchfield and Wilcoxon (1949).

#### Results

[0088] Table 2 below demonstrates the data produced in this experiment, and Figure 1 illustrates these results.

25 [0089] In the vehicle group, the CC<sub>50</sub> value was calculated to be 25.7mA.

[0090] In the positive control diazepam (2.5 mg/kg) treated group, administered i.p. 30 minutes before the test, the CC<sub>50</sub> value was 57.5mA. In the sodium valproate (250 mg/kg) treated group, administered i.p. 30 minutes before the test, the CC<sub>50</sub> value was 281.5mA. These results were statistically significant (p<0.001) compared to the vehicle control.

30 [0091] In the 6-OH CBDV treatment groups, administered i.p. 15, 15, and 30 minutes before the test, the doses of 3, 10 and 30 mg/kg 6-OH CBDV produced a statistically significant CC<sub>50</sub> value compared to vehicle at all three doses of the compound.

[0092] Such data are indicative that this compound will be of therapeutic benefit.

35 **Table 2: Evaluation of effect of 6-OH CBDV in the MEST test**

| Treatment | Dose | N | Pre- | CC <sub>50</sub> ± SEM | % change | Significance |
|-----------|------|---|------|------------------------|----------|--------------|
|-----------|------|---|------|------------------------|----------|--------------|

|                  | (mg/kg) |    | treatment time (mins) |             | from vehicle |         |
|------------------|---------|----|-----------------------|-------------|--------------|---------|
| Vehicle          | -       | 12 | 15                    | 25.7 ± 0.4  | -            | -       |
| Diazepam         | 2.5     | 12 | 30                    | 57.5 ± 0.3  | 124%         | P<0.001 |
| Sodium Valproate | 250     | 12 | 30                    | 281.5 ± 5.8 | 997%         | P<0.001 |
| 6-OH CBD         | 3       | 12 | 15                    | 54.2 ± 1.4  | 111%         | P<0.001 |
| 6-OH CBD         | 10      | 12 | 15                    | 63.5 ± 3.4  | 147%         | P<0.001 |
| 6-OH CBD         | 30      | 12 | 30                    | 92.5 ± 0.4  | 260%         | P<0.001 |

### **Conclusions**


**[0093]** 6-OH CBDV produced a dose-related increase in MEST, which provides evidence that this compound exhibits anticonvulsive properties. Significant effects were observed at 3, 10, and 30 mg/kg, when compared to vehicle.

**[0094]** These data are significant as they provide heretofore unknown evidence that this cannabinoid may be of therapeutic value.

**CLAIMS**

1. 6-hydroxy cannabidivarin (6-OH CBDV) for use as a medicament.  
5
2. 6-OH CBDV for use according to claim 1, wherein the 6-OH CBDV is in the form of a synthetic compound.
3. 6-OH CBDV for use according to claim 1, wherein the 6-OH CBDV is in the form of a  
10 pure or isolated compound.
4. 6-OH CBDV for use according to any of the preceding claims, wherein the dose of 6-OH CBDV is greater than 100 mg/kg/day.
- 15 5. 6-OH CBDV for use according to any of the preceding claims, wherein the dose of 6-OH CBDV is less than 100 mg/kg/day.
6. A composition for use as a medicament comprising 6-hydroxy cannabidivarin (6-OH CBDV) and one or more pharmaceutically acceptable excipients.  
20
7. 6-hydroxy cannabidivarin (6-OH CBDV) for use in the treatment of epilepsy.
8. 6-OH CBDV for use according to claim 7, wherein the epilepsy treated is in a mammal.
- 25 9. 6-OH CBDV for use according to claim 8, wherein the mammal is a human.
10. 6-OH CBDV for use according to claim 8, wherein the mammal is a dog.
11. A process for the preparation of 6-hydroxy cannabidivarin (6-OH CBDV).  
30

Figure 1. Effect of 6-OH Cannabidiol (6-OH CBDV) on the electroshock-induced generalised seizure threshold (MEST) in the mouse



\* P<0.05; \*\* P<0.01; \*\*\* P<0.001 Significant change in threshold when compared to own vehicle

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2020/052944

A. CLASSIFICATION OF SUBJECT MATTER  
 INV. A61K31/05 A61P25/08  
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X         | <p>LANDER N ET AL: "TOTAL SYNTHESSES OF CANNABIDIOL AND DELTA1-TETRAHYDROCANNABINOL METABOLITES", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, UK, vol. 1, 1 January 1976 (1976-01-01), pages 8-16, XP001073667, ISSN: 0300-922X, DOI: 10.1039/P19760000008<br/>           the whole document<br/>           page 9, left-hand column, paragraph 2<br/>           page 10, right-hand column, paragraph 2<br/>           page 14, left-hand column, last paragraph<br/>           - right-hand column, paragraph 2<br/>           -----<br/>           -/--</p> | 11                    |



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

20 January 2021

Date of mailing of the international search report

01/02/2021

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040,  
 Fax: (+31-70) 340-3016

Authorized officer

Economou, Dimitrios

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2020/052944

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X         | GB 2 527 599 A (GW PHARMA LTD [GB])<br>30 December 2015 (2015-12-30)<br>the whole document<br>claims 1-10   | 1-10                  |
| X         | -----<br>US 6 630 507 B1 (HAMPSON AIDAN J [US] ET<br>AL) 7 October 2003 (2003-10-07)<br>cited in the application<br>the whole document<br>column 1, line 10 - line 15<br>column 3, line 1 - line 10<br>column 3, line 23 - line 35<br>column 5, line 26 - line 67<br>column 8, line 45 - line 65<br>column 9, line 29 - line 35<br>example 9<br>compounds 46-47<br>claims 1,2,13<br>----- | 1-10                  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2020/052944

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |            |
|--|------------------|-------------------------|------------------|------------|
| GB 2527599                             | A                | 30-12-2015              | EP 3160457 A1    | 03-05-2017 |
|  |                  |                         | EP 3639814 A1    | 22-04-2020 |
|  |                  |                         | ES 2769863 T3    | 29-06-2020 |
|  |                  |                         | GB 2527599 A     | 30-12-2015 |
|  |                  |                         | US 2017209390 A1 | 27-07-2017 |
|  |                  |                         | US 2020206152 A1 | 02-07-2020 |
|  |                  |                         | WO 2015198078 A1 | 30-12-2015 |
|  |                  |                         | -----            |            |
| US 6630507                             | B1               | 07-10-2003              | AT 367809 T      | 15-08-2007 |
|  |                  |                         | AU 766988 B2     | 30-10-2003 |
|  |                  |                         | CA 2329626 A1    | 28-10-1999 |
|  |                  |                         | EP 1071419 A1    | 31-01-2001 |
|  |                  |                         | JP 2002512188 A  | 23-04-2002 |
|  |                  |                         | US 6630507 B1    | 07-10-2003 |
|  |                  |                         | WO 9953917 A1    | 28-10-1999 |
|  |                  |                         | -----            |            |